Rational selection and application of anti- hypertensive drugs in patients with chronic kidney disease

doi:10.3877/cma.j.issn.2095-3216.2016.01.002

Abstract

Abstract:

As a traditional risk factor for cardiovascular disease, hypertension plays a critical role in the progression of chronic kidney disease (CKD). Hypertension is not only one of the major causes of CKD, but the most common complication of it. Hypertension management can help to both delay the progression of CKD and reduce the incidence of cardiovascular events. Because the etiology and progression of CKD are complex, the rational selection and application of anti- hypertensive drugs are very important..

Key words: Chronic kidney disease, Hypertension, Treatment

Yani He, Lirong Lin. Rational selection and application of anti- hypertensive drugs in patients with chronic kidney disease[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2016, 05(01): 5-9.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2016.01.002

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2016/V05/I01/5

References 42

1	Segall L, Oprisiu R, Fournier A, et al. Antihypertensive treatment and stroke prevention in patients with and without chronic kidney disease: a review of controlled trials [J]. J Nephrol, 2008, 21(3): 374-83.
2	Heerspink HJ, Ninomiya T, Zoungas S, et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta- analysis of randomised controlled trials [J]. Lancet, 2009, 373(9668): 1009-1015.
3	Mancia G, De Backer G, Dominiczak A, et al. 2007 ESH- ESC practice guidelines for the management of arterial hypertension: ESH- ESC task force on the management of arterial hypertension [J]. J Hypertens, 2007, 25(9): 1751-1762.
4	Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) [J]. J Hypertens, 2013, 31(7): 1281-1357.
5	James PA, Oparil S, Carter BL, et al. 2014 evidence- based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) [J]. JAMA, 2014, 311(5): 507-520.
6	中国高血压防治指南修订委员会．中国高血压防治指南2010[J]．中华高血压杂志，2011，19(8): 701-742.
7	Appel L, Wright JT Jr, Greene T. Intensive blood- pressure control in hypertensive chronic kidney disease [J]. N Engl J Med, 2010, 363(10): 918-929.
8	Ruggenenti P, Perna A, Loriga G, et al. Blood- pressure control for reno- protection in patients with non- diabetic chronic renal disease (REIN- 2): multicentre, randomised controlled trial [J]. Lancet, 2005, 365(9463): 939-946.
9	KDIGO Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease [J]. Kidney Inter Suppl, 2012, 2(5): 337-414.
10	Raymond R. Blood pressure targets in CKD [J]. Adv Chronic Kidney Dis, 2015, 22(2): 96-101.
11	Kovesdy CP, Bleyer AJ, Molnar MZ, et al. Blood pressure and mortality in US veterans with chronic kidney disease: a cohort study [J]. Ann Intern Med, 2013, 159(4): 233-242.
12	Poulter NR, Prabhakaran D, Caulfield M. Hypertension [J]. Lancet, 2015, 386(9995): 801-812.
13	Cohen HW, Hailpern SM, Fang J, et al. Sodium intake and mortality in the NHANES II follow- up study [J]. Am J Med, 2006, 119(3): 275.e7-275.e14.
14	O′Donnell M, Mente A, Rangarajan S, et al. Urinary sodium and potassium excretion, mortality, and cardiovascular events [J]. N Engl J Med, 2014, 371(7): 612-623.
15	Humalda JK, Navis G. Dietary sodium restriction: a neglected therapeutic opportunity in chronic kidney disease [J]. Curr Opin Nephrol Hypertens, 2014, 23(6): 533-540.
16	Burnier M, Wuerzner G. Chronic kidney disease: Should sodium intake be restricted in patients with CKD [J]? Nat Rev Nephrol, 2014, 10(7): 363-364.
17	Fan Li, Tighiouart H, Levey AS, et al. Urinary sodium excretion and kidney failure in nondiabetic chronic kidney disease [J]. Kidney Int, 2014, 86(3): 582-588.
18	Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial [J]. JAMA, 2002, 288(19): 2421-2431.
19	Tocci G, Volpe M. End- organ protection in patients with hypertension: focus on the role of angiotensin receptor blockers on renal function [J]. Drugs, 2011, 71(8): 1003-1017.
20	Vishram JK, Borglykke A, Andreasen AH, et al. Impact of age on the importance of systolic and diastolic blood pressures for stroke risk: the MOnica, Risk, Genetics, Archiving, and Monograph (MORGAM) Project [J]. Hypertension, 2012, 60(5): 1117-1123.
21	Balamuthusamy S, Srinivasan L, Verma M, et al. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta- analysis[J]. Am Heart J, 2008, 155(5): 791-805.
22	Chan KE, Ikizler TA, Gamboa JL, et al. Combined angiotensin converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients [J]. Kidney Int, 2011, 80(9): 978-985.
23	Ryan MJ, Tuttle KR. Elevations in serum creatinine with RAAS blockade: why isn't it a sign of kidney injury [J]? Curr Opin Nephrol Hypertens, 2008, 17(5): 443-449.
24	Bakris GL, Weir MR. Angiotensin- converting enzyme inhibitor- associated elevations in serum creatinine: is this a cause for concern [J]? Arch Intern Med, 2000, 160(5): 685-693.
25	K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients [J]. Am J Kidney Dis, 2005, 45(4 Suppl 3): S1-S153.
26	Palmer SC, Mavridis D, Navarese E, et al. Comparative efficacy and safety of blood pressure- lowering agents in adults with diabetes and kidney disease: a network meta- analysis[J]. Lancet, 2015, 385(9982): 2047-2056.
27	Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta- analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies [J]. BMJ, 2009, 338: b1665.
28	Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol [J]. Lancet, 2002, 359(9311): 995-1003.
29	Ptinopoulou AG, Pikilidou M, Lasaridis AN. The effect of antihypertensive drugs on chronic kidney disease: a comprehensive review [J]. Hypertens Res, 2013, 36(2): 91-101.
30	Badve SV, Roberts MA, Hawley CM, et al. Effects of beta- adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta- analysis [J]. J Am Coll Cardiol, 2011, 58(11): 1152-1161.
31	Tangri N, Shastri S, Tighiouart H, et al. β- Blockers for prevention of sudden cardiac death in patients on hemodialysis: a propensity score analysis of the HEMO Study [J]. Am J Kidney Dis, 2011, 58(6): 939-945.
32	Bakris GL, Sarafidis PA, Weir MR, et al. Renal outcomes with different fixed- dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a pre- specified secondary analysis of a randomised controlled trial [J]. Lancet, 2010, 375(9721): 1173-1181.
33	Mann JF, Anderson C, Gao P. Dual inhibition of the renin- angiotensin system in high- risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trial [J]. J Hypertens, 2013, 31(2): 414-421.
34	Agarwal R, Flynn J, Pogue V, et al. Assessment and management of hypertension in patients on dialysis [J]. J Am Soc Nephrol, 2014, 25(8): 1630-1646.
35	Agarwal R, Satyan S, Alborzi P, et al. Home blood pressure measurements for managing hypertension in hemodialysis patients [J]. Am J Nephrol, 2009, 30(2): 126-134.
36	Lingerfelt K, Hodnicki D. Hypertension management in patients receiving hemodialysis: the benefits of home blood pressure monitoring [J]. Nephrol Nurs J, 2012, 39(1): 31-36.
37	Haskin O, Wong CJ, McCabe L. 44- h ambulatory blood pressure monitoring: revealing the true burden of hypertension in pediatric hemodialysis patients [J]. Pediatr Nephrol, 2015, 30(4): 653-660.
38	Ram CV, Fenves AZ. Management of hypertension in hemodialysis patients [J]. Curr Hypertens Rep, 2009, 11(4): 292-298.
39	Tang X, Hu X, Mei C, et al. Improvement of resistant hypertension by nocturnal hemodialysis in a patient with end- stage kidney disease [J]. Case Rep Nephrol Dial, 2015, 5(1): 60-65.
40	Kestenbaum B, Gillen DL, Sherrard DJ, et al. Calcium channel blocker use and mortality among patients with end- stage renal disease [J]. Kidney Int, 2002, 61(6): 2157-2164.
41	Cice G, Ferrara L, D'Andrea A, et al. Carvedilol increases two- year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo- controlled trial [J]. J Am Coll Cardiol, 2003, 41(9): 1438-1444.
42	Agarwal R, Sinha AD, Pappas MK, et al. Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial [J]. Nephrol Dial Transplant, 2014, 29(3): 672-681.

[1]	Hongyu Wang. Application value of fixed and mobile platform prostheses in total knee arthroplasty [J]. Chinese Journal of Joint Surgery(Electronic Edition), 2023, 17(06): 871-876.
[2]	Shanwu Li, Yongjie Ye, Bing Wang, Ziyi Wang, Yi Yin, Guanjun Sun, Dagang Zhang. Early efficacy comparison of open wedge high tibial osteotomy and unicompartmental knee arthroplasty [J]. Chinese Journal of Joint Surgery(Electronic Edition), 2023, 17(06): 882-888.
[3]	Zhengwen Xu, Zhen Li, Zhenyang Hou, Changzheng Su, Biao Zhu. Platelet rich plasma combined with bone grafting for treatment of early non-traumatic osteonecrosis of femoral head [J]. Chinese Journal of Joint Surgery(Electronic Edition), 2023, 17(06): 773-779.
[4]	Xu Peng, Yongfu Shao, Duo Li, Rui Zhou, Zhenming Xing. Diagnosis and surgical treatment of hepatocolon flexure [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 108-110.
[5]	Weiqiang Ma, Binlin Ma, Zhongyu Wu, Ying Zhang. The role of microRNA in the progression of triple-negative breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 111-114.
[6]	Jianmei Li, Jingjuan Deng, Qian Yang. Safety and follow-up evaluation of the combined treatment of hepatocellular carcinoma with hepatic cirrhosis and portal hypertension [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 41-44.
[7]	Haitao Zhang, Chanjuan Kang, Jingjie Zhai. Effect of pancreatic duct stent implantation in the treatment of acute biliary pancreatitis [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 654-657.
[8]	Xue Yang, Wei Zhang, Peizhong Shang, Chuangye Song, Dandan Shang, Wei Zhang. Cholecystoduodenal fistula with stone draining through it and spontaneously healing：a case report [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 707-708.
[9]	Yao Chen, Boqun Xu, Zhihui Gao. Efficacy and safety of modified intermediate upper approach radical resection in the treatment of thyroid cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 619-622.
[10]	Ming Jiang, Rui Luo, Chengchao Long. Diagnosis and treatment of obturator hernia: An experience of 73 cases over 10 years [J]. Chinese Journal of Hernia and Abdominal Wall Surgery(Electronic Edition), 2023, 17(06): 706-710.
[11]	Qikun Zhang, Fuchao Shang, Qi Li, Guangming Li, Menglong Wang. Survival benefit of combined splenectomy in patients with liver cancer complicated with portal hypertension after radical resection [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 613-618.
[12]	Bing Lan, Huaiming Wang, Hui Wang, Bo Ma. Research progress on locally advanced colon cancer with bladder invasion [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(06): 505-511.
[13]	Zhifeng Lu, Jiajia Zhou, Shu Liang. Advances in application and research of virtual reality technology in amblyopia treatment [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(08): 891-895.
[14]	Tian Li, Hong Xu, Heliang Liu. Progress in research of pneumoconiosis [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(08): 900-905.
[15]	Cheng Yi, Wei Wei, Yuliang Zhao. The last piece of picture puzzle: conceptual evolution of acute kidney disease [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(08): 906-910.

Please choose a citation manager

Content to export